Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02293707 | A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer | completed | Phase 2 | 99 | Laboratoires Leurquin MediolanumINDUSTRY | 2 | Jul 22, 2020 | clinicaltrials |
| NCT01867424 | Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2020 | clinicaltrials |
| NCT01036594 | Ketoconazole and Dexamethasone in Prostate Cancer(Keto/Dex) | completed | Phase 2 | 32 | University of California, San FranciscoOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT03617588 | 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer(PRONOUNCED) | completed | Phase 2 | 49 | Theragnostics LtdINDUSTRY | 1 | Jun 24, 2020 | clinicaltrials |
| NCT03199872 | RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours | completed | Phase 1 / Phase 2 | 22 | RhoVac APSINDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT00105053 | Vaccine Treatment for Hormone Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 8 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT00025116 | ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 40 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01560923 | Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer | completed | Phase 2 | 47 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01599793 | Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer | completed | Phase 2 | 19 | University of ChicagoOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT03124433 | Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer | completed | Phase 2 | 30 | Singapore General HospitalOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT02077634 | Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)(SPARE) | completed | Phase 2 | 68 | Universität des SaarlandesOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT01790126 | The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer | completed | Phase 2 | 90 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 11, 2020 | clinicaltrials |
| NCT03264456 | Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI | completed | Phase 1 / Phase 2 | 18 | University of Alabama at BirminghamOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT01923727 | Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer(IAB2M) | completed | Phase 1 / Phase 2 | 38 | ImaginAb, Inc.INDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02349022 | Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy | completed | Phase 2 | 19 | ImaginAb, Inc.INDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01787331 | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer | completed | Phase 2 | 21 | University of California, San FranciscoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02095145 | Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2020 | clinicaltrials |
| NCT01446991 | Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy | completed | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02429193 | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA(BARRIER-P) | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00002602 | Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer | completed | Phase 1 / Phase 2 | 1,084 | Radiation Therapy Oncology GroupNETWORK | 2 | Jan 10, 2020 | clinicaltrials |
| NCT02830880 | FACBC Prostate Therapy Response | completed | Phase 2 | 7 | Emory UniversityOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03191968 | Prostate Cancer Survivors and Exercise and Behavioral Counseling(BOOST) | completed | Phase 2 | 27 | University of Illinois at Urbana-ChampaignOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02344017 | Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer(DUALIDES) | completed | Phase 1 / Phase 2 | 23 | Orion Corporation, Orion PharmaINDUSTRY | 4 | Dec 19, 2019 | clinicaltrials |
| NCT00450749 | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2019 | clinicaltrials |
| NCT00003238 | Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00022412 | Doxercalciferol Before Surgery in Treating Localized Prostate Cancer | completed | Phase 2 | 60 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01946165 | Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | completed | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT02726113 | Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy | completed | Phase 2 | 50 | Medical University of South CarolinaOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02918357 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence(PSMA BCR) | completed | Phase 2 / Phase 3 | 385 | University of California, San FranciscoOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT00582556 | Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy | completed | Phase 2 | 44 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00214097 | Phase I/II Hypofractionated Radiotherapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 347 | University of Wisconsin, MadisonOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00849121 | Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 17 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00488982 | Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 125 | University of California, San FranciscoOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT03365297 | Therapeutics in Active Prostate Cancer Surveillance(TAPS01) | completed | Phase 2 | 11 | CCTU- Cancer ThemeOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00106418 | A Research Study for Patients With Prostate Cancer | completed | Phase 2 | 35 | CelgeneINDUSTRY | 0 | Nov 18, 2019 | clinicaltrials |
| NCT00030602 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | — | University of Maryland, BaltimoreOTHER | 0 | Nov 5, 2019 | clinicaltrials |
| NCT00003400 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 45 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00005028 | Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 46 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00456989 | Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 39 | University of LouisvilleOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01146340 | Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer(PHART6) | completed | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01585246 | Saw Palmetto: Symptom Management for Men During Radiation Therapy | completed | Phase 1 / Phase 2 | 48 | Michigan State UniversityOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT01204710 | A Study of Olaratumab (IMC-3G3) in Prostate Cancer | completed | Phase 2 | 123 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 20, 2019 | clinicaltrials |
| NCT01987999 | Eradication of Prostate Cancer Using F-989 | completed | Phase 2 | 60 | Optimal Health ResearchOTHER | 0 | Sep 20, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT00831792 | TKI258 in Castrate Resistant Prostate Cancer | completed | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02141490 | Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02279862 | Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 9 | Aug 28, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2020source: clinicaltrials